Active — Not RecruitingNot Applicable

Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes

United States533 participantsStarted 2021-01-14

Plain-language summary

The aim of this study is to assess the prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes receiving care at Joslin clinic using noninvasive imaging and serum-based methods with the goal of identifying high-risk patients with advanced fibrosis who should be prioritized for specialty referral

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Subject is male or female
✓. Subject age between 18-75 years old
✓. Subject with an established diagnosis of T1D for at least three months prior to screening

Exclusion criteria

✕. Subject is pregnant or lactating
✕. Subject has an active malignancy
✕.Subject with secondary causes of fatty liver including history of any of the following:

What they're measuring

Proportion of subjects with NAFLD

Timeframe: Baseline (one time point evaluation)

Proportion of subjects with advanced fibrosis

Timeframe: Baseline (one time point evaluation)

Trial details

NCT IDNCT04595474

SponsorJoslin Diabetes Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-08-19

View on ClinicalTrials.gov More Nonalcoholic Fatty Liver trials